...
首页> 外文期刊>Theranostics >Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief
【24h】

Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief

机译:用Ropivacaine加载的脂质体和营养剥夺联合治疗,同时癌症治疗和癌症疼痛缓解

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Autophagy allows cancer cells to respond changes in nutrient status by degrading and recycling non-essential intracellular contents. Inhibition of autophagy combined with nutrient deprivation is an effective strategy to treat cancer. Pain is a primary determinant of poor quality of life in advanced cancer patients, but there is currently no satisfactory treatment. In addition, effective treatment of cancer does not efficiently relieve cancer pain, but may increase pain in many cases. Hence, few studies focus on simultaneous cancer therapy and pain relief, and made this situation even worse. Method: Ropivacaine was loaded into tumor-active targeted liposomes. The cytotoxicity of ropivacaine-based combination therapy in B16 and HeLa cells were tested. Moreover, a mice model of cancer pain which was induced by inoculation of melanoma near the sciatic nerve was constructed to assess the cancer suppression and pain relief effects of ropivacaine-based combination therapy. Results: Ropivacaine and ropivacaine-loaded liposomes (Rop-DPRL) were novelly found to damage autophagic degradation. Replicated administration of Rop-DPRL and calorie restriction (CR) could efficiently repress the development of tumor. In addition, administration of Rop-DPRL could relieve cancer pain with its own analgestic ability in a short duration, while repeated administration of Rop-DPRL and CR resulted in continuous alleviation of cancer pain through reduction of VEGF-A levels in advanced cancer mice. Further, dual inhibition of phosphorylation of STAT3 at Tyr705 and Ser727 by Rop-DPRL and CR contribute to the reduction of VEGF-A. Conclusion: Combination therapy with Rop-DPRL and nutrient deprivation simultaneously suppresses cancer growth and relieves cancer pain.? The author(s).
机译:自噬使癌细胞通过降解和再循环非必需的细胞内含量来反应营养状况的变化。抑制自噬联合营养剥夺是治疗癌症的有效策略。疼痛是晚期癌症患者生活质量差的主要决定因素,但目前没有令人满意的治疗。此外,癌症的有效治疗没有有效地缓解癌症疼痛,但在许多情况下可能会增加疼痛。因此,很少有研究专注于同时癌症治疗和疼痛缓解,并使这种情况变得更糟。方法:将Ropivacaine加载到肿瘤活性靶向脂质体中。测试了基于Ropivaine的组合疗法在B16和HeLa细胞中的细胞毒性。此外,通过在坐骨神经附近接种黑色素瘤诱导的癌症疼痛的小鼠模型,以评估基于Ropivacaine的组合疗法的癌症抑制和疼痛缓解效应。结果:Ropivacaine和Ropivacaine加载的脂质体(ROP-DPRL)是新的,以损害自噬降解。 ROP-DPRL和卡路里限制(CR)的复制给药可以有效地抑制肿瘤的发育。此外,ROP-DPR1的给药可以在短时间内以自己的分支能力缓解癌症疼痛,而重复施用ROP-DPR1和CR通过降低晚期癌症小鼠的VEGF-A水平,导致癌症疼痛持续减轻癌症疼痛。此外,通过ROP-DPR1和CR在TYR705和SER727在TYR705和SER727的磷酸化的双重抑制有助于降低VEGF-A。结论:用ROP-DPR1和营养剥夺的联合治疗同时抑制癌症生长并减轻癌症疼痛。作者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号